Head of Trade & Patient Services

About the role

Location: Warren, NJ

The Head of Trade and Patient Services will be a founding commercial leader responsible for designing, building, and executing DBV's end-to-end trade strategy and patient support infrastructure in the United States. This individual will serve as the strategic architect of how VIASKIN® Peanut reaches patients — from pharmacy network design and distribution strategy through patient access programs, hub services, and adherence support. Given VIASKIN® Peanut's patch-based administration and a pediatric patient population requiring ongoing engagement, this leader will need to balance operational rigor with deep patient-centricity, anticipating the unique journey of allergic children and their caregivers navigating a first-of-its-kind therapy.

DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians who believed that food allergies could one day be treated safely and effectively. We are on a mission to advance epicutaneous immunotherapy using our innovative technology platform, Viaskin™, to develop treatment options for immunologic diseases with significant unmet medical need. This mission drives our commitment to the advancement of treatments for patients and their families. That is why we are investigating a potential new class of immunotherapy, epicutaneous immunotherapy (EPIT), that aims to re-educate the immune system of patients through the skin. Today, we are focused on exploring the use of Viaskin to address food allergies, a devastating condition that afflicts millions of patients. As an important milestone in our journey, we hope to offer the first epicutaneous immunotherapy treatment for peanut allergy. Tomorrow, as pioneers, we will continue to explore the broad applications of this potential new class of immunotherapy, including treatments for patients suffering from inflammatory and autoimmune diseases.

Responsibilities

• Trade & Distribution Strategy: Design and implement the U.S. trade channel strategy, including specialty pharmacy (SP) network architecture, specialty distributor (SD) relationships, and limited distribution model (LDM) framework appropriate for a biologics patch product; lead contracting negotiations with specialty pharmacies, hub service providers; structure agreements to optimize patient access and commercial performance; partner with Finance, Legal, and Market Access to develop and manage gross-to-net (GTN) assumptions, chargeback processes, returns policy, and inventory management practices; establish trade analytics capabilities, including sell-in/sell-through reporting, inventory tracking,